Skip to main content


With more than 40 states reporting an increase in overdose deaths during the COVID-19 pandemic, the American Medical Association, in partnership with the firm Manatt Health, has published an update to its National Roadmap on State-Level Efforts to End the Nation’s Drug Overdose Epidemic.
Spark Biomedical, a Texas-based medical device company, announced that the FDA has granted 510(k) clearance for its Sparrow Therapy System, a wearable neurostimulation device for the treatment of opioid withdrawal.
While providers wait for vaccines to slow the COVID-19 pandemic and better treatments to reduce the death toll among those infected, there are steps that can be taken to help address the “other” surge—in the opioid crisis.
UC Health in Cincinnati announced that it is seeking patients for a study of opioid addiction treatment using an extended-release formulation buprenorphine in pregnant women.
With the lethality, availability and use of stimulants all greatly increasing in the U.S. in recent years and the COVID-19 pandemic complicating the treatment landscape for patients and practitioners alike, it’s critical for providers to weather the storm, Deni Carise, PhD, chief science officer for Recovery Centers of America, told Cocaine, Meth & Stimulant Summit attendees in a Saturday session.
Back to Top